EA202191165A1 - Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы - Google Patents

Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы

Info

Publication number
EA202191165A1
EA202191165A1 EA202191165A EA202191165A EA202191165A1 EA 202191165 A1 EA202191165 A1 EA 202191165A1 EA 202191165 A EA202191165 A EA 202191165A EA 202191165 A EA202191165 A EA 202191165A EA 202191165 A1 EA202191165 A1 EA 202191165A1
Authority
EA
Eurasian Patent Office
Prior art keywords
breast cancer
elacestrant
abemacyclibus
women
combination
Prior art date
Application number
EA202191165A
Other languages
English (en)
Russian (ru)
Inventor
Нина К. Арагам
Чарльз Моррис
Original Assignee
Радиус Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Радиус Фармасьютикалс, Инк. filed Critical Радиус Фармасьютикалс, Инк.
Publication of EA202191165A1 publication Critical patent/EA202191165A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA202191165A 2018-11-30 2019-11-26 Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы EA202191165A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773960P 2018-11-30 2018-11-30
PCT/US2019/063239 WO2020112765A1 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Publications (1)

Publication Number Publication Date
EA202191165A1 true EA202191165A1 (ru) 2021-09-21

Family

ID=68966023

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191165A EA202191165A1 (ru) 2018-11-30 2019-11-26 Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы

Country Status (18)

Country Link
US (3) US20220117963A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886826A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022509262A (cg-RX-API-DMAC7.html)
KR (1) KR20210097170A (cg-RX-API-DMAC7.html)
CN (1) CN113164415A (cg-RX-API-DMAC7.html)
AU (1) AU2019388900B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010169A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120368A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191165A1 (cg-RX-API-DMAC7.html)
IL (1) IL283502A (cg-RX-API-DMAC7.html)
JO (1) JOP20210125A1 (cg-RX-API-DMAC7.html)
MA (1) MA54293A (cg-RX-API-DMAC7.html)
MX (1) MX2021005876A (cg-RX-API-DMAC7.html)
MY (1) MY209833A (cg-RX-API-DMAC7.html)
PH (1) PH12021551235A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105455RA (cg-RX-API-DMAC7.html)
UA (1) UA129403C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020112765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック, インコーポレイテッド Gdc-9545とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384605B (es) * 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
WO2017160990A1 (en) * 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer

Also Published As

Publication number Publication date
US20250268899A1 (en) 2025-08-28
IL283502A (en) 2021-07-29
JP2022509262A (ja) 2022-01-20
CA3120368A1 (en) 2020-06-04
JOP20210125A1 (ar) 2019-11-26
KR20210097170A (ko) 2021-08-06
MA54293A (fr) 2021-10-06
WO2020112765A1 (en) 2020-06-04
MY209833A (en) 2025-08-07
BR112021010169A2 (pt) 2021-08-17
SG11202105455RA (en) 2021-06-29
AU2019388900B2 (en) 2025-09-04
MX2021005876A (es) 2021-07-16
US20260014153A1 (en) 2026-01-15
UA129403C2 (uk) 2025-04-16
JP2025094216A (ja) 2025-06-24
CN113164415A (zh) 2021-07-23
US20220117963A1 (en) 2022-04-21
AU2019388900A1 (en) 2021-06-10
EP3886826A1 (en) 2021-10-06
PH12021551235A1 (en) 2021-12-13

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MY189536A (en) Subcutaneous her2 antibody formulations
MY186977A (en) Tetrasubstituted alkene compounds and their use
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
SG10201902664RA (en) Combination therapy for treating cancer
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2020002229A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
MX2020001727A (es) Terapia de combinacion.
TW201613578A (en) Pharmaceutical combinations
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
MX2021007477A (es) Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.